General Information of Drug Off-Target (DOT) (ID: OTJWHIQG)

DOT Name T-cell surface glycoprotein CD3 gamma chain (CD3G)
Synonyms T-cell receptor T3 gamma chain; CD antigen CD3g
Gene Name CD3G
Related Disease
Combined immunodeficiency due to CD3gamma deficiency ( )
UniProt ID
CD3G_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1SY6; 6JXR; 7FJD; 7FJE; 7FJF; 7PHR; 7Q5U; 8ES7; 8ES8; 8ES9
Pfam ID
PF16680 ; PF02189
Sequence
MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGK
MIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLF
AEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLR
RN
Function
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways. In addition to this role of signal transduction in T-cell activation, CD3G plays an essential role in the dynamic regulation of TCR expression at the cell surface. Indeed, constitutive TCR cycling is dependent on the di-leucine-based (diL) receptor-sorting motif present in CD3G.
KEGG Pathway
Hematopoietic cell lineage (hsa04640 )
Th1 and Th2 cell differentiation (hsa04658 )
Th17 cell differentiation (hsa04659 )
T cell receptor sig.ling pathway (hsa04660 )
Chagas disease (hsa05142 )
Measles (hsa05162 )
Human T-cell leukemia virus 1 infection (hsa05166 )
Epstein-Barr virus infection (hsa05169 )
Human immunodeficiency virus 1 infection (hsa05170 )
PD-L1 expression and PD-1 checkpoint pathway in cancer (hsa05235 )
Reactome Pathway
Downstream TCR signaling (R-HSA-202424 )
Phosphorylation of CD3 and TCR zeta chains (R-HSA-202427 )
Translocation of ZAP-70 to Immunological synapse (R-HSA-202430 )
Generation of second messenger molecules (R-HSA-202433 )
FCGR activation (R-HSA-2029481 )
Regulation of actin dynamics for phagocytic cup formation (R-HSA-2029482 )
Role of phospholipids in phagocytosis (R-HSA-2029485 )
PD-1 signaling (R-HSA-389948 )
Cargo recognition for clathrin-mediated endocytosis (R-HSA-8856825 )
Clathrin-mediated endocytosis (R-HSA-8856828 )
FCGR3A-mediated IL10 synthesis (R-HSA-9664323 )
FCGR3A-mediated phagocytosis (R-HSA-9664422 )
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933 )

Molecular Interaction Atlas (MIA) of This DOT

1 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Combined immunodeficiency due to CD3gamma deficiency DISZB70D Definitive Autosomal recessive [1]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
2 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate decreases the methylation of T-cell surface glycoprotein CD3 gamma chain (CD3G). [2]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene affects the methylation of T-cell surface glycoprotein CD3 gamma chain (CD3G). [5]
------------------------------------------------------------------------------------
5 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Tretinoin DM49DUI Approved Tretinoin increases the expression of T-cell surface glycoprotein CD3 gamma chain (CD3G). [3]
Acetaminophen DMUIE76 Approved Acetaminophen increases the expression of T-cell surface glycoprotein CD3 gamma chain (CD3G). [4]
Calcitriol DM8ZVJ7 Approved Calcitriol increases the expression of T-cell surface glycoprotein CD3 gamma chain (CD3G). [3]
(+)-JQ1 DM1CZSJ Phase 1 (+)-JQ1 decreases the expression of T-cell surface glycoprotein CD3 gamma chain (CD3G). [6]
KOJIC ACID DMP84CS Investigative KOJIC ACID decreases the expression of T-cell surface glycoprotein CD3 gamma chain (CD3G). [7]
------------------------------------------------------------------------------------

References

1 Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
2 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
3 Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
4 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
5 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
6 BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012 Dec;92(6):1147-54. doi: 10.1189/jlb.0312165. Epub 2012 Jul 16.
7 Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006 Apr;29(4):655-69.